Search - tctmd.com

Displaying 101 - 120 of 134

Sort: Relevancy | Date

Presentation TCT 2013

Device and Clinical Trial Update: Vessix (Boston Scientific)

Presenter: Ajay Kirtane

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Symplicity and Spyral (Medtronic)

Presenter: David Kandzari

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Paradise (ReCor Medical)

Presenter: Thomas Zeller

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: OneShot (Covidien)

Presenter: John Ormiston

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: EnligHTN (St. Jude)

Presenter: Stephen Worthley

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Cordis Renal Denervation Approach

Presenter: Marc Sapoval

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Allegro/Iberis (Angiocare/Terumo)

Presenter: Xiongjing Jiang

October 27, 2013

Presentation TCT 2013

The Spectrum of Current and Future Renal Denervation Clinical Trials

Presenter: Mehdi Shishehbor

October 27, 2013

News Daily News

Renal Denervation Safe, Effective for Moderate Resistant Hypertension in Pilot Study

July 19, 2013

News Daily News

EnligHTN I Published: Renal Denervation with Multielectrode Catheter Safe, Effective

Caitlin E. Cox

July 05, 2013

News Daily News

EnligHTN I Publicado: La Denervación Renal con Catéter Multielectrodo es Segura y Eficaz

Caitlin E. Cox

July 05, 2013

News Daily News

Renal Denervation Lowers Ambulatory BP Measurements in Resistant Hypertension

June 28, 2013

News Daily News

Meta-analysis: Renal Denervation Effective Regardless of Catheter Type

L.A. McKeown

May 17, 2013

News Daily News

Imaging Detects Vascular Injury Arising from Catheter-Based Renal Denervation

Caitlin E. Cox

May 03, 2013

News Daily News

ESC Provides Guidance on Appropriate Use of Catheter-Based Renal Denervation

April 26, 2013

News Daily News

Remote Postconditioning Reduces AKI in NSTEMI Patients

March 15, 2013

News Industry News

New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity™ Renal Denervation System

March 09, 2013

Presentation TCT 2012

The Clinical Use of Renal Denervation Is Already Expanding Beyond Trial Indications: Insights from the German GREAT Registry

Presenter: Felix Mahfoud

October 24, 2012

News Daily News

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

L.A. McKeown

September 18, 2012

News Daily News

Model Suggests Renal Denervation Cost-effective for Resistant Hypertension

September 13, 2012

Advertisement

Device and Clinical Trial Update: Vessix (Boston Scientific)

Device and Clinical Trial Update: Symplicity and Spyral (Medtronic)

Device and Clinical Trial Update: Paradise (ReCor Medical)

Device and Clinical Trial Update: OneShot (Covidien)

Device and Clinical Trial Update: EnligHTN (St. Jude)

Device and Clinical Trial Update: Cordis Renal Denervation Approach

Device and Clinical Trial Update: Allegro/Iberis (Angiocare/Terumo)

The Spectrum of Current and Future Renal Denervation Clinical Trials

Renal Denervation Safe, Effective for Moderate Resistant Hypertension in Pilot Study

EnligHTN I Published: Renal Denervation with Multielectrode Catheter Safe, Effective

EnligHTN I Publicado: La Denervación Renal con Catéter Multielectrodo es Segura y Eficaz

Renal Denervation Lowers Ambulatory BP Measurements in Resistant Hypertension

Meta-analysis: Renal Denervation Effective Regardless of Catheter Type

Imaging Detects Vascular Injury Arising from Catheter-Based Renal Denervation

ESC Provides Guidance on Appropriate Use of Catheter-Based Renal Denervation

Remote Postconditioning Reduces AKI in NSTEMI Patients

New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity™ Renal Denervation System

The Clinical Use of Renal Denervation Is Already Expanding Beyond Trial Indications: Insights from the German GREAT Registry

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

Model Suggests Renal Denervation Cost-effective for Resistant Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content